{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.5","value":"-0.5"},{"groupId":"OG001","spread":"21.7","value":"-0.4"}]}],"title":"Week 44, Calculated/Blood (n=41,40)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"53.0","value":"6.9"},{"groupId":"OG001","spread":"37.3","value":"3.9"}]}],"title":"Week 44, Measured/Urinalysis (n=37,37)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.9","value":"-0.7"},{"groupId":"OG001","spread":"20.3","value":"-4.3"}]}],"title":"Week 92, Calculated/Blood (n=41,40)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"45.6","value":"3.1"},{"groupId":"OG001","spread":"39.1","value":"2.0"}]}],"title":"Week 92, Measured/Urinalysis (n=37,37)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"CrCl was calculated from blood samples using the Cockcroft-Gault formula, and was also measured by urinalysis. The percent change in CrCl was calculated as \\[Week 44 or 92 CrCl minus Baseline CrCl\\] divided by Baseline CrCl, multiplied by 100. For the Week 44 analysis, the last available value on/before Week 44 was used in the calculation. For the Week 92 analysis, the last available value on/before Week 92 was used in the calculation.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with multiple myeloma received ibandronate via 15-minute IV infusion as 6 mg every 4 weeks for up to 92 weeks. As a result of slow recruitment, the treatment duration was shortened to 40 weeks for participants who had not yet received 48 weeks of treatment. All participants returned for an additional follow-up observation 4 weeks after the end of treatment.","id":"OG000","title":"Ibandronate"},{"description":"Participants with multiple myeloma received zoledronate via 15-minute IV infusion as 4 mg every 4 weeks for up to 92 weeks. As a result of slow recruitment, the treatment duration was shortened to 40 weeks for participants who had not yet received 48 weeks of treatment. All participants returned for an additional follow-up observation 4 weeks after the end of treatment.","id":"OG001","title":"Zoledronate"}],"paramType":"MEAN","populationDescription":"ITT Population. The \"Number of Participants Analyzed\" reflects the total number of participants who provided evaluable data for the endpoint. The number of participants who provided data within the specified timeframe for each analysis (n) is shown in the table.","reportingStatus":"POSTED","timeFrame":"Baseline and Weeks 44, 92","title":"Percent Change From Baseline in CrCl","type":"SECONDARY","unitOfMeasure":"percent change"}